MicroRNAs as clinical tools for diagnosis, prognosis, and therapy in prostate cancer

• DOI: 10.1016/j.tranon.2022.101613
• Publication Date: 2023-01-05T03:33:24Z
• Authors: Fatima Ghamlouche; Amani Yehya; Yousef Zeid; Hiam Fakhereddine; Jhonny Fawaz; Yen-Nien Liu; Mohamed Al-Sayegh; Wassim Abou-Kheir
• Keywords: Diagnostic/prognostic biomarkers; 0301 basic medicine; MicroRNAs; 0303 health sciences; 03 medical and health sciences; Prostate cancer; High-throughput profiling technologies; Therapeutic tools; Commentary; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; RC254-282; 3. Good health

Prostate cancer (PCa) is one of the most commonly diagnosed cancers among men worldwide. Despite presence accumulated clinical strategies for PCa management, limited prognostic/sensitive biomarkers are available to follow up on disease occurrence and progression. MicroRNAs (miRNAs) small non-coding RNAs that control gene expression through post-transcriptional regulation their complementary target messenger RNA (mRNA). MiRNAs modulate fundamental biological processes play crucial roles in pathology various diseases, including PCa. Multiple evidence proved an aberrant miRNA profile PCa, which actively involved carcinogenic process. The robust pleiotropic impact miRNAs suggests them as potential candidates help more understand molecular landscape disease, likely provide tools early diagnosis prognosis well additional therapeutic manage prostate tumors. Here, we emphasize consistently reported dysregulated highlight contribution altered downstream targets with hallmarks. Also, report effectiveness using diagnostic/prognostic high-throughput profiling technologies being used detection. Another key aspect be discussed this review promising implication molecules fighting